[Cost-minimization study on the prescription of intravenous proton pump inhibitors: pantoprazole versus omeprazole].
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D001562:Benzimidazoles / Q000191:economics* / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D004791:Enzyme Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000191:economics* / Q000627:therapeutic use*; D000077402:Pantoprazole; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D013454:Sulfoxides / Q000191:economics* / Q000627:therapeutic use*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole
Estudio de minimización de costes en la prescripción de inhibidores de la bomba de protones intravenosos: pantoprazol versus omeprazol.